CG Oncology, Inc. (CGON)

In the past six months, CG Oncology's stock has experienced significant positive movements. In late April 2025, the company announced superior efficacy data from cohorts of its late-stage BOND-003 study, leading to a 26.5% rally in its shares within a month. As of October 2025, the share price had surged 60% over the past 90 days and climbed 44.7% year-to-date, driven by optimism around its clinical trial progress and sustained "Buy" ratings from analysts. In August 2025, CG Oncology reported impressive durability data for cretostimogene grenadenorepvec in the BOND-003 Cohort C trial and announced a favorable legal verdict against ANI Pharmaceuticals. In September 2025, Morgan Stanley boosted CGON's price target to $79. In October 2025, Guggenheim initiated coverage with a "Buy" rating and a $90 price target, JP Morgan also maintained its "Overweight" recommendation and raised its price target from $41 to $47, and an insider significantly enhanced his stake with an investment of approximately $50 million.

There is no specific information available regarding demand seasonality for CG Oncology, Inc.'s products and services. Demand for its products, if approved, would likely be driven by disease prevalence and treatment needs rather than seasonal fluctuations.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer, operating in the Biotechnology & Medical Research sector. The company's lead product candidate is cretostimogene grenadenorepvec (CG0070), an intravesically delivered oncolytic immunotherapy agent designed to selectively infect and replicate within tumor cells, leading to their destruction and the activation of an anti-tumor immune response. Cretostimogene is in various stages of clinical development for different bladder cancer indications, including the BOND-003 Phase 3 trial, CORE-001 Phase 2 trial, PIVOT-006 Phase 3 trial, CORE-008 Phase 2 clinical trial, and CORE-002 in development.

CG Oncology is headquartered in Irvine, California, United States, and has a global presence with employees across five continents, including North America, Asia, and Africa. The company has an exclusive license, development, and commercialization agreement with Kissei Pharmaceutical Co., Ltd. for its CG0070 drug in Japan, South Korea, Taiwan, and other Asian countries, with the exception of China.

CG Oncology's brand reputation in the past year appears to be strong and positive, primarily driven by promising clinical trial results and favorable analyst and investor sentiment. Positive analyst outlooks, including "Strong Buy" ratings and increased price targets from firms like Guggenheim, Morgan Stanley, and J.P. Morgan, reflect considerable confidence in its clinical approach and future potential. The unanimous "Buy" ratings from all analysts covering the stock further underscore this positive reputation. Additionally, a favorable legal verdict against ANI Pharmaceuticals, eliminating future royalty obligations, would also contribute positively to the company's reputation.

CG Oncology, Inc. has significant institutional ownership, with 390 institutional owners and shareholders holding a total of 83,730,682 shares. Major institutional owners include Decheng Capital LLC, Vanguard Group Inc, BlackRock, Inc., Fmr Llc, TCG Crossover Management, LLC, Braidwell Lp, Kynam Capital Management, LP, UBS Group AG, Foresite Capital Management VI LLC, State Street Corp, Longitude Capital Management Co., LLC, Kissei Pharmaceutical Co., Ltd., and ORI Capital. The largest individual shareholder is Hong Fang Song, owning 7.04 million shares, representing 9.23% of the company.